Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease

Movement Disorders : Official Journal of the Movement Disorder Society
Chiara FiorentiniCristina Missale

Abstract

Dyskinesia, the major side effect of l-dopa therapy in PD, is mainly associated with nonphysiological stimulation of denervated receptors in the striatum. In particular, DA D1 receptor-mediated aberrant extracellular signal-regulated protein kinases 1 and 2 activation have been associated with striatal changes leading to dyskinesia. We recently identified the tyrosine phosphatase Shp-2 as a crucial effector transmitting D1 receptor signaling to extracellular signal-regulated protein kinases 1 and 2 activation and reported the involvement of the D1 receptor/Shp-2/extracellular signal-regulated protein kinases 1 and 2 pathway in the development of l-dopa-induced dyskinesia. In this study, the role of Shp-2 in l-dopa-induced dyskinesia development was investigated by in vivo silencing of Shp-2 in the striatum of the 6-hydroxy-dopamine rat model of PD. Lentiviral particles delivering short hairpin RNA were used to obtain long-term striatal Shp-2 downregulation. Rats were then treated with l-dopa and analyzed for both the improvement of akinesia and the development of l-dopa-induced dyskinesia. The results show that Shp-2 knockdown remarkably decreased extracellular signal-regulated protein kinases 1 and 2 phosphorylation and attenu...Continue Reading

References

Oct 29, 2000·Trends in Neurosciences·J A ObesoJ G Nutt
Apr 1, 2003·Nature Neuroscience·Barbara PicconiPaolo Calabresi
Apr 5, 2003·Journal of Neurochemistry·Li-Qing JinEitan Friedman
Jun 27, 2003·Trends in Biochemical Sciences·Benjamin G NeelLily Pao
Jan 28, 2004·Annual Review of Pharmacology and Toxicology·Per SvenningssonPaul Greengard
Jun 26, 2004·Annual Review of Neuroscience·Raul R GainetdinovMarc G Caron
Dec 21, 2004·Proceedings of the National Academy of Sciences of the United States of America·Emmanuel ValjentJean-Antoine Girault
Apr 13, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Giovanni FabbriniChristopher G Goetz
Jun 29, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Emanuela SantiniGilberto Fisone
Mar 21, 2008·Biochemical Pharmacology·Wei-Dong YaoJingping Zhang
Jul 5, 2008·Psychopharmacology·Rose-Marie KarlssonAndrew Holmes
Sep 11, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·John G Nutt
May 23, 2009·Molecular Pharmacology·Lifen ZhangJohn A Dani
Mar 27, 2010·Current Pharmaceutical Design·Latanya M ScottJie Wu
Apr 23, 2010·Science Translational Medicine·Mohamed R AhmedErwan Bezard
Aug 5, 2010·Proceedings of the National Academy of Sciences of the United States of America·Helen S BateupPaul Greengard
Oct 5, 2010·Frontiers in Neuroanatomy·Pedro Barroso-Chinea, Erwan Bezard
Oct 9, 2012·The Journal of Clinical Investigation·Gregory PorrasErwan Bezard
May 21, 2014·Nature Reviews. Clinical Oncology·Yujie Zhao, Alex A Adjei

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.